Candesartan prevented development of diabetes mellitus in heart failure: COMMENTARY

Gutknecht, David R.
January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p11
Academic Journal
This article comments on a clinical study according to which type 2 diabetes, which is closely linked to obesity and cardiovascular disease, may be preventable through weight control, lifestyle changes, and the use of such drugs as metformin and thiazolidinediones. The authors of the study did a preplanned subgroup analysis of data from 3 parallel placebo-controlled trials with varying inclusion criteria. Patients had different levels of LVEF, but all had symptomatic heart failure. Diabetes was most convincingly prevented in patients with preserved systolic function, with little benefit observed in those already receiving an ACE inhibitor. The overall 21% relative risk reduction is similar to that reported in other trials, involving almost 40,000 patients.


Related Articles

  • Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Matsuzaki, Masunori; Hori, Masatsugu; Izumi, Tohru; Asanoi, Hidetsugu; Tsutamoto, Takayoshi // Cardiovascular Drugs & Therapy;Dec2011 Supplement 1, Vol. 25, p19 

    Purpose: Tolvaptan may reduce the signs of volume overload in heart failure (HF) patients who experience volume overload despite using conventional diuretics. In this study, we evaluated the dose-response effects of tolvaptan on weight loss, urine volume and electrolyte excretion in...

  • Promising weight loss programme. Denby, Martin // New Zealand Doctor;6/6/2007, p25 

    The article stresses the importance of a weight loss programme for diabetic patients. The author says that lifestyle changes make a difference in weight loss. He reports that the Diabetes Prevention Program found that a 7% weight loss can lessen the onset of type 2 diabetes by 58%. He adds that...

  • In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. Dans, Antonio L.; Koon Teo; Gao, Peggy; Jyh-Hong Chen; Kim Jae-Hyung; Yusoff, Khalid; Chaitraphan, Suphachai; Zhu, Jun; Liu Lisheng; Yusuf, Salim // PLoS Clinical Trials;Dec2010, Vol. 7 Issue 12, Special section p1 

    Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia...

  • Clinical briefs.  // New Zealand Doctor;11/18/2009, p15 

    This section offers medical news briefs. A study from Great Britain has found that a daily injection of the diabetic drug liraglutide is better for weight loss than orlistat and placebo. Researchers from Great Britain has found that basal insulin is the best first choice when adding insulin to...

  • ORLISTAT FOR WEIGHT LOSS MAINTENANCE.  // Pulse;5/3/2007, Vol. 67 Issue 17, p42 

    The article focuses on the effect of long-term orlistat in weight loss maintenance among the patients in Great Britain. Study shows that patients weighed between 75 kilogram and 162 kilogram had one or more cardiac risk factors. It was found out that orlistat patients weighed an average 9.4...

  • Lisinopril/hydrochlorothiazide.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p25 

    An abstract of the article "Intraoperative cardiac arrest: Was it the ACE inhibitor?," by J. Bjerregaard and colleagues is presented.

  • Pramlintide Injection.  // AHFS Consumer Medication Information;Aug2017, p1 

    Pramlintide is used with mealtime insulin to control blood sugar levels in people who have diabetes. Pramlintide is only used to treat patients whose blood sugar could not be controlled by insulin or insulin and an oral medication for diabetes. Pramlintide is in a class of medications called...

  • ACE inhibitors can prevent diabetes and heart failure.  // GP: General Practitioner;3/24/2003, p17 

    According to the results of a trial the angiotensin converting enzyme (ACE) inhibitors could prevent heart failure (HF) among patients at high risk of cardiovascular events. The ‘Heart Outcomes Prevention Evaluation’ (HOPE) study found ramipril cut the development rate of HF among...

  • Hypertension: Which drugs to choose for patients with cardiovascular disease. Wexler, Randy; Feldman, David // Journal of Family Practice;Apr2006, Vol. 55 Issue 4, p291 

    The article presents recommendations for treating patients with cardiovascular diseases such as heart failure, coronary artery disease and stroke. Hypertension is linked to heart failure cases, heart attacks and first-time strokes. A study was conducted that aims to identify a drug that will...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics